In this episode, we discuss the pathbreaking use of an encapsulated cell therapy that produces CNTF for the successful treatment of MacTel with Roger Goldberg, MD, from Walnut Creek, CA.

In our latest update, we discuss strategies for developing a teleretinology network with Dr. Glenn Yiu, Professor of Ophthalmology, University of California, Davis.

In our latest update we discuss the prevention and treatment of endophthalmitis with one of the world's leading authorities, Dr. Harry Flynn , holder of the J. Donald M. Gass Distinguished Chair In Ophthalmology at the Bascom Palmer Eye Institute.

We discuss early studies of ophthalmic artery angioplasty in cases of advanced geographic atrophy with Dr. Philip Rosenfeld of the Bascom Palmer Eye Institute.

In our latest episode, we discuss the results of the PRIMA retinal implant in treating eyes with center involved geographic atrophy as presented in a recent New England Journal of Medicine article. 85% of eyes had meaningful improvement in vision at one year with Dr. Daniel Palanker, Professor of Ophthalmology and Electrical Engineering, Stanford University.

In this episode, In our latest episode,  we discuss the results of a randomized trial comparing the Iluvien sustained release steroid implant to aflibercept in the treatment of diabetic macular edema with Dr. Michael Singer, Clinical Professor, University of Texas Health Sciences Center, San Antonio.

We discuss the diagnosis and management of central serous chorioretinopathy with photodynamic therapy with Dr. Andrew Lotery, Professor of Ophthalmology, University of Southhampton, United Kingdom.

In this episode, we discuss the use of low dose cryogenic application for anesthesia prior to intravitreal injection with Dr. Michael Singer, Adjunct Professor University of Texas Health Science Center, San Antonio.

In our latest update, we discuss current treatment of retinopathy of prematurity as well as new developments in disease prevention with Dr. Darius Moshfeghi, Professor of Ophthalmology, Stanford University, Director, Retina Division, Byers Eye Institute.

In this update, we review the TKI program of Eyepoint Pharmaceuticals with Dr. Jay Duker, President and CEO.